Breast cancer is the number one malignant tumor threatening Chinese women’s health. On the International Women's Day, Eli Lilly and Company China announced that its new breast cancer drug, CDK4&6 inhibitor Visele (abexiclib tablets), was officially launched in China. Millions of breast cancer patients in China have a new life. of survival expectations.
Professor Shao Zhimin from the Cancer Hospital of Fudan University believes that the successful launch of Vicho (abexiclib tablets) in mainland China will further change the survival outcomes of Chinese breast cancer patients and is expected to enable more patients to live longer. Longer, live better.
Extended information
Breast cancer will become the cancer with the highest number of new cases in the world in 2020:
Among various subtypes of advanced breast cancer, HR and HER2 -The most common, accounting for about 60%. The latest statistics from the International Agency for Research on Cancer show that breast cancer has surpassed lung cancer in 2020 and has become the cancer with the highest number of new cases in the world. In 2020 alone, China had 416,000 new breast cancer cases and approximately 117,000 deaths, accounting for approximately 17.1% of global breast cancer deaths.
According to Eli Lilly, clinical trials show that abeciclib combined with an aromatase inhibitor or fulvestrant can improve HR and progression-free survival in patients with HER2- advanced breast cancer compared with endocrine therapy alone.
Interface News-On Women’s Day, a drug that can treat early breast cancer is on the market